<DOC>
	<DOC>NCT02622932</DOC>
	<brief_summary>The purpose of this study is to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer patients.</brief_summary>
	<brief_title>Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients</brief_title>
	<detailed_description />
	<criteria>signed and dated informed consent histologically or cytologically confirmed diagnosis of advanced solid tumor (including RCC、NSCLC、STS and CRC) failed to the treatment of line 1 or 2 ECOG PS:01,Life expectancy of more than 3 months main organs function is normal prior treatment with Anlotinib or Allergic to drug or its formulation ingredients subjects with the gastrointestinal tract, liver and kidney disease of affect drug absorption and metabolism CTCAE(4.0) Grade 1 or higher nonremission toxicity induced by any other previous treatments patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2 or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount of activities, affecting Instrumental activities of daily life]) patients underwent major surgical treatment，open biopsy or significant traumatic injury within 28 days prior to assignment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>